Contemporary analysis of secondary failure of successful sulfonylurea therapy

Endocrine Practice

Volumn 13, Issue 1, 2007, Pages 37-44

  Nichols, Gregory A ^a   Alexander, Charles M ^b   Girman, Cynthia J ^b   Kamal Bahl, Sachin J ^b   Brown, Jonathan B ^a  

^a CENTER FOR HEALTH RESEARCH   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN; SULFONYLUREA DERIVATIVE;

ADULT; AGED; ARTICLE; FACTUAL DATABASE; FEMALE; HEALTH MAINTENANCE ORGANIZATION; HUMAN; HYPERGLYCEMIA; MALE; METABOLISM; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PREDICTION AND FORECASTING; PROPORTIONAL HAZARDS MODEL; TREATMENT FAILURE;

ADULT; AGED; DATABASES, FACTUAL; DIABETES MELLITUS, TYPE 2; FEMALE; HEALTH MAINTENANCE ORGANIZATIONS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; SULFONYLUREA COMPOUNDS; TREATMENT FAILURE;

EID: 34147189634     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: 10.4158/EP.13.1.37     Document Type: Article

References (22)

1. Groop LC, Pelkonen R, Koskimies S, Bottazzo GF, Doniach D. Secondary failure to treatment with oral antidiabetic agents in non-insulin-dependent diabetes. Diabetes Care. 1986;9:129-133.
2. Matthews DR, Cull CA, Stratton IM, Holman RR, Turner RC (UK Prospective Diabetes Study [UKPDS] Group). UKPDS 26: sulphonylurea failure in non-insulin dependent diabetic patients over six years. Diabet Med. 1998;15:297-303.
3. Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA. 2002;287: 360-372.
4. Nichols GA, Gomez-Caminero A. Weight changes following the initiation of new anti-hyperglycaemic therapies. Diabetes Obes Metab. 2007;9:96-102.
5. Johansen K. Efficacy of metformin in the treatment of NIDDM: meta-analysis. Diabetes Care. 1999;22: 33-37.
6. Bailey CJ, Turner RC. Metformin. N Engl J Med. 1996;334:574-579.
7. Turner RC, Cull CA, Frighi V, Holman RR (UK Prospective Diabetes Study [UKPDS] Group). Glycemic control with diet, sulphonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA. 1999;281:2005-2012.
8. Boccuzzi SJ, Wogen J, Fox J, Sung JC, Shah AB, Kim J. Utilization of oral antihyperglycemic agents in a drug-insured U.S. population. Diabetes Care. 2001;24:1411-1415.
9. Eurich DT, Simpson SH, Majumdar SR, Johnson JA. Secondary failure rates associated with metformin and sulfonylurea therapy for type 2 diabetes. Pharmacotherapy. 2005;25:810-816.
10. Cook MN, Girman CJ, Stein PP, Alexander CM, Holman RR. Glycemic control continues to deteriorate after sulfonylureas are added to metformin among patients with type 2 diabetes. Diabetes Care. 2005;28:995-1000.
11. Nichols GA, Alexander CM, Girman CJ, Kamal-Bahl S, Brown JB. Treatment escalation and rise in HbA1c following successful initial metformin therapy. Diabetes Care. 2006;29:504-509.
12. American Diabetes Association. Standards of medical care for patients with diabetes mellitus: position statement. Diabetes Care. 2002;25(Suppl 1):S33-S49.
13. Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol. 1997;50:105-116.
14. Hertz RP, Unger AN, Lustik MB. Adherence with pharmacotherapy for type 2 diabetes: a retrospective cohort study of adults with employer-sponsored health insurance. Clin Ther. 2005;27:1064-1073.
15. Haffner SM (American Diabetes Association). Management of dyslipidemia in adults with diabetes. Diabetes Care. 2003;26(Suppl 1):S83-S86.
16. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) [erratum in Lancet. 1998;352:1558]. Lancet. 1998;352:854-865.
17. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) [erratum in Lancet. 1999;354:602]. Lancet. 1998;352:837-853.
18. Nathan DM, Cleary PA, Backland JY, et al (Diabetes Control and Complications Trial/ Epidemiology of Diabetes Interventions and Complications [DCCT/EDIC] Study Research Group). Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353:2643-2653.
19. American Diabetes Association. Standards of medical care for patients with diabetes mellitus: clinical practice recommendations 2006. Diabetes Care. 2006;29(Suppl 1):S1-S85.
20. Brown JB, Nichols GA, Perry A. The burden of treatment failure in type 2 diabetes. Diabetes Care. 2004;27:1535-1540.
21. United Kingdom Prospective Diabetes Study Group. United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. Ann Intern Med. 1998;128:165-175.
22. Grant RW, Singer DE, Meigs JB. Medication adherence before an increase in antihypertensive therapy: a cohort study using pharmacy claims data. Clin Ther. 2005;27:773-781.